Developer docs
API playgroundTry for free, no card

Search company profiles

Vectron Biosolutions

Full company profile

uuid0003o5p

Namestring
Vectron Biosolutions
Legal namestring
Vectron Biosolutions AS
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Vectron Biosolutions AS, founded in 2008 and headquartered in Trondheim, Norway, is a privately held biotechnology company that commercializes proprietary vector technologies developed at the Norwegian University of Science and Technology (NTNU). The company engineers tailor-made microbial production strains in E. coli for clients in the pharmaceutical, food technology, and industrial enzyme sectors. Its offering is anchored on three complementary technology platforms: VB Expression (a modular vector platform combining proprietary promoters, signal peptides, fusion partners, and copy number regulators around a tunable xylS/Pm expression system), VB Evolution (a directed evolution pipeline with ultra-high-throughput screening capable of generating millions of randomized vectors to identify optimal configurations), and VB Secretion (a proprietary secretion platform acquired from T3S Technologies in 2021 that uses engineered flagella to export proteins extracellularly, reducing downstream processing burden). Supporting components include CYT Tags (N-terminal cytoplasmic fusion partners), signal peptide libraries for Sec and Tat pathways, and the granted Dual UTR synthetic 5'-UTR patent.

The company operates a fee-for-service strain development model structured around five work packages (feasibility study, genetic optimization, cultivation optimization, fed-batch optimization, and research cell bank delivery), with multi-year contracts, project-based engagement, and willingness to structure profit- or risk-sharing arrangements. On project completion, strains are transferred to customers under license agreements that may include patent applications covering the customer's specific production strain, providing the customer with extended IP insulation. The company also generates revenue through technology and patent licensing. Headcount is in the 11-50 range, focused primarily on scientific staff. Distribution is a mix of direct enterprise sales (targeting pharma, CMOs, and industrial enzyme manufacturers) and channel partners including Sartorius Korea Biotech Co. (exclusive agent for the Republic of Korea since April 2022) and Cytovance Biologics (North American CDMO partner since October 2023).

Short descriptiontext

Vectron Biosolutions develops tailor-made E. coli protein production strains for pharmaceutical, food technology, and industrial enzyme clients, using its proprietary VB Expression, VB Evolution, and VB Secretion technology platforms under a fee-for-service and licensing model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTrondheim, Norway
HQ citystring
Trondheim
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbial protein production, recombinant expression vectors, strain development services, protein secretion technology, E. coli expression systems
Industry3 codes
PRIMARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Microbial protein production services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Strain Development Services
TypeProfessional Services
Description

Fee-for-service based strain development projects with up to 5 work packages. Projects include feasibility studies, genetic optimization, cultivation optimization, fed-batch optimization, and delivery of research cell bank with full documentation. Can include profit-sharing/risk-sharing models.

vectronbiosolutions.com
2Technology Licensing
TypeLicensing Royalties
Description

After strain development, strains transferred under license agreement with proprietary rights to customer for use in manufacturing. Customers receive exclusive license to use developed strains for intended purposes.

vectronbiosolutions.com
3Patent Licensing
TypeLicensing Royalties
Description

Patent applications claiming use of Vectron technologies for production of customer proteins may be part of project deliverables, providing customers with additional IP protection.

vectronbiosolutions.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Technology or R&D
Pricing details2 tiers
1Feasibility Study (WP01)
ModelOtherBilling cadenceMulti-year contract
Notes

Initial screening of plasmid copy number, signal peptides, fusion partners, expression strength, and chaperones. Results determine project continuation.

vectronbiosolutions.com
2Full Strain Development Project
ModelOtherBilling cadenceMulti-year contract
Notes

5 work packages with go/no-go decisions: feasibility, genetics optimization, cultivation optimization, fed-batch optimization, research cell bank. Custom quotes based on protein complexity.

vectronbiosolutions.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vectron Biosolutions develops tailor-made E. coli expression vector technologies and provides bespoke bacterial strain development services for recombinant protein production. The company delivers engineered production strains and research cell banks to pharmaceutical, biomanufacturing, and industrial enzyme customers, leveraging three proprietary technology platforms (VB Expression, VB Evolution, VB Secretion) under multi-phase project engagements that typically conclude with licensing of the developed strain to the customer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Record titers >60 g/L for E. coli produced proteins
+6 more records
Product overview1 text field

Vectron Biosolutions offers a technology platform for microbial protein production, consisting of three core proprietary technologies: VB Expression (modular expression vector platform combining expression elements), VB Evolution (directed evolution approach creating novel vectors), and VB Secretion (microbial secretion technology). Supporting technologies include VB Expert, VB Solutions, and CYT Tags. The company provides strain development services including feasibility studies, genetic optimization, cultivation optimization, and research cell bank creation. In 2024, they expanded services to include enzyme evolution, fermentation scale-up, upstream process characterization, purification, and protein analysis services.

Product and service7 records
1Tailor-Made Strain Development Services
CategoryStrain development service
Description

Bespoke bacterial strain development service that engineers unique E. coli production strains optimized for each customer's specific protein, delivering maximal titers of biologically active, soluble protein. Projects follow up to 5 work packages and result in research cell bank delivery under license with proprietary rights to the customer.

2Feasibility Studies
CategoryStrain development service
Description

Initial screening and assessment service (WP01) evaluating plasmid copy number, signal peptides, fusion partners, expression strength, and chaperones to determine the optimal approach for producing a customer's target protein and whether to proceed with a full strain development project.

3Fermentation Services
CategoryProcess development service
Description

Scale-up service progressing engineered strains from bench to pilot scale under industrially relevant high cell density cultivation conditions, including fed-batch optimization. Processes frequently yield 10-60 g/L.

4Enzyme Evolution and Screening
CategoryEnzyme engineering service
Description

Service evaluating evolved enzyme activity and characterizing new variants to identify improved enzymatic processes for industrial and specialty enzyme customers.

5Protein Analysis Services
CategoryAnalytical service
Description

Comprehensive product quality assessment including intact mass, glycan and disulfide bond profiling, in-vitro characterization, activity, binding affinity, and titer determination for customer proteins.

6Upstream Process Characterization
CategoryProcess development service
Description

Service supporting characterization of upstream fermentation processes for customer protein production, complementing strain development and fermentation services.

7Purification and Protein Quality Assessment
CategoryDownstream processing service
Description

Downstream processing service supporting purification of customer proteins from engineered E. coli strains, complementing upstream strain development and fermentation services.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-10
Description

Strategic international collaboration to integrate Vectron's E. coli strain development services with Cytovance's microbial CDMO manufacturing capabilities. Enables customers to access complete package from gene to product for US market. Vectron brings next-generation vector engineering technologies while Cytovance provides cGMP manufacturing capacity including 1000L fermenters.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-20
Description

Partnership to develop next-generation animal-free proteins through precision fermentation. Vectron provides strain development expertise and proprietary expression technologies. Motif uses these for food technology applications including HEMAMI dairy alternatives and APPETEX texture enhancers. Expanded from existing 2-year collaboration.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-04-01
Description

Exclusive distribution agreement making Sartorius Korea the exclusive agent for Vectron products and services in Republic of Korea. Provides Korean biotech and pharma companies easier access to Vectron's next-generation technologies for recombinant protein production.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2019-05-29
Description

Non-exclusive collaboration offering superior complete solution for microbial production of therapeutic proteins. Combines Vectron's state-of-the-art strain development with Mycenax's cost-efficient manufacture from experienced CMO with great track record.

Strategic tierSecondaryTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-12-20
Description

Non-exclusive license agreement for recombinant expression of enzymes. Collaboration on two projects showed high success rate on large set of target enzymes in discovery pipeline and high yields in scaled-up production.

Strategic tierSecondaryTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2016-10-26
Description

License agreement for commercial rights to use Vectron's expression vector technology platform for manufacture of Candida antarctica CalB enzyme for biocatalysis applications. Includes right to combine with EnginZyme's proprietary EziG immobilization matrix.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Partnership to engineer genetically stable E. coli strains optimized for perfusion fermentation. Scarab's early results show protein production sustained for nearly 60 days - approximately 20 times longer than typical E. coli strains. Combining with VB Secretion technology for extended fermentation processes.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting Partner
Description

Research partner for Fab therapeutic protein production project funded by Norwegian Research Council. SINTEF contributes extensive experience with fed-batch fermentation to help develop Fab production processes targeting >10 g/L soluble Fabs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ATUM (formerly DNA2.0) provides proprietary expression vectors and microbial protein production services; directly comparable as a strain-engineering / protein-expression CRO with comparable target customers.

TypeDirect peer
Description

Cube Biotech offers expression systems and services for protein production in E. coli and other hosts, including difficult-to-express targets — directly overlapping with Vectron's tailor-made E. coli strain development offering.

TypeDirect peer
Description

ProteoGenix is a CRO providing recombinant protein expression and production services across hosts including E. coli; comparable customer base of biotech and pharma developers needing custom strain or construct work.

TypeEmerging player
Description

Bota Bio is a synthetic biology / microbial biomanufacturing platform building engineered strains for industrial and specialty applications; comparable as a venture-backed microbial strain development platform, though broader in scope.

TypeBroad incumbent
Description

Codexis engineers enzymes and proteins for pharmaceutical and industrial applications using directed evolution (CodeEvolver) — directly comparable technology overlap with Vectron's VB Evolution directed-evolution platform.

TypeBroad incumbent
Description

Ginkgo operates a much broader synthetic biology platform including cell engineering and protein production programs; comparable as a large-scale microbial engineering incumbent competing for similar strain-development wallet share.

TypeBroad incumbent
Description

Twist provides synthetic DNA and antibody discovery/optimization services; adjacent to Vectron as an upstream provider enabling protein expression workflows, though broader and more diversified across life sciences.

TypeDirect peer
Description

Cytovance is a microbial CDMO partnered with Vectron; comparable as a downstream microbial manufacturing provider and a partner that competes for similar strain-development-and-manufacturing opportunities.

TypeDirect peer
Description

Scarab engineers stabilized E. coli strains and partners with Vectron on perfusion fermentation; comparable as a specialized E. coli engineering company serving similar difficult-protein production applications.

TypeBroad incumbent
Description

WuXi Biologics is a global biologics CDMO with microbial and mammalian capabilities; relevant benchmark as a scaled incumbent serving the same pharma/biotech customers who might otherwise engage Vectron for strain development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vectron Biosolutions

Microbial protein production servicesvectronbiosolutions.com

Vectron Biosolutions develops tailor-made E. coli protein production strains for pharmaceutical, food technology, and industrial enzyme clients, using its proprietary VB Expression, VB Evolution, and VB Secretion technology platforms under a fee-for-service and licensing model.

What Vectron Biosolutions does

Vectron Biosolutions AS, founded in 2008 and headquartered in Trondheim, Norway, is a privately held biotechnology company that commercializes proprietary vector technologies developed at the Norwegian University of Science and Technology (NTNU). The company engineers tailor-made microbial production strains in E. coli for clients in the pharmaceutical, food technology, and industrial enzyme sectors. Its offering is anchored on three complementary technology platforms: VB Expression (a modular vector platform combining proprietary promoters, signal peptides, fusion partners, and copy number regulators around a tunable xylS/Pm expression system), VB Evolution (a directed evolution pipeline with ultra-high-throughput screening capable of generating millions of randomized vectors to identify optimal configurations), and VB Secretion (a proprietary secretion platform acquired from T3S Technologies in 2021 that uses engineered flagella to export proteins extracellularly, reducing downstream processing burden). Supporting components include CYT Tags (N-terminal cytoplasmic fusion partners), signal peptide libraries for Sec and Tat pathways, and the granted Dual UTR synthetic 5'-UTR patent.

The company operates a fee-for-service strain development model structured around five work packages (feasibility study, genetic optimization, cultivation optimization, fed-batch optimization, and research cell bank delivery), with multi-year contracts, project-based engagement, and willingness to structure profit- or risk-sharing arrangements. On project completion, strains are transferred to customers under license agreements that may include patent applications covering the customer's specific production strain, providing the customer with extended IP insulation. The company also generates revenue through technology and patent licensing. Headcount is in the 11-50 range, focused primarily on scientific staff. Distribution is a mix of direct enterprise sales (targeting pharma, CMOs, and industrial enzyme manufacturers) and channel partners including Sartorius Korea Biotech Co. (exclusive agent for the Republic of Korea since April 2022) and Cytovance Biologics (North American CDMO partner since October 2023).

Vectron Biosolutions firmographics

Firmographics
Name
Vectron Biosolutions
Legal name
Vectron Biosolutions AS
Website
https://vectronbiosolutions.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
Vectron Biosolutions develops tailor-made E. coli protein production strains for pharmaceutical, food technology, and industrial enzyme clients, using its proprietary VB Expression, VB Evolution, and VB Secretion technology platforms under a fee-for-service and licensing model.
Ownership category
akta.pro rank

Vectron Biosolutions industry classification

Industry
Product category
Microbial protein production services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Microbial protein production
  • Recombinant expression vectors
  • Strain development services
  • Protein secretion technology
  • E. coli expression systems

Where Vectron Biosolutions is headquartered

Location

Headquarters

HQ city
Trondheim
HQ country
Norway
HQ region
Europe

Offices1 record

Markets served

Vectron Biosolutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D

Revenue model

  1. Strain Development Services: Fee-for-service based strain development projects with up to 5 work packages. Projects include feasibility studies, genetic optimization, cultivation optimization, fed-batch optimization, and delivery of research cell bank with full documentation. Can include profit-sharing/risk-sharing models.
  2. Technology Licensing: After strain development, strains transferred under license agreement with proprietary rights to customer for use in manufacturing. Customers receive exclusive license to use developed strains for intended purposes.
  3. Patent Licensing: Patent applications claiming use of Vectron technologies for production of customer proteins may be part of project deliverables, providing customers with additional IP protection.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFeasibility Study (WP01)
OtherMulti-year contractFull Strain Development Project

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Vectron Biosolutions product offering

Product offering

Core offering

Vectron Biosolutions develops tailor-made E. coli expression vector technologies and provides bespoke bacterial strain development services for recombinant protein production. The company delivers engineered production strains and research cell banks to pharmaceutical, biomanufacturing, and industrial enzyme customers, leveraging three proprietary technology platforms (VB Expression, VB Evolution, VB Secretion) under multi-phase project engagements that typically conclude with licensing of the developed strain to the customer.

Product overview

Vectron Biosolutions offers a technology platform for microbial protein production, consisting of three core proprietary technologies: VB Expression (modular expression vector platform combining expression elements), VB Evolution (directed evolution approach creating novel vectors), and VB Secretion (microbial secretion technology). Supporting technologies include VB Expert, VB Solutions, and CYT Tags. The company provides strain development services including feasibility studies, genetic optimization, cultivation optimization, and research cell bank creation. In 2024, they expanded services to include enzyme evolution, fermentation scale-up, upstream process characterization, purification, and protein analysis services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tailor-Made Strain Development Services Bespoke bacterial strain development service that engineers unique E. coli production strains optimized for each customer's specific protein, delivering maximal titers of biologically active, soluble protein. Projects follow up to 5 work packages and result in research cell bank delivery under license with proprietary rights to the customer.
  • Feasibility Studies Initial screening and assessment service (WP01) evaluating plasmid copy number, signal peptides, fusion partners, expression strength, and chaperones to determine the optimal approach for producing a customer's target protein and whether to proceed with a full strain development project.
  • Fermentation Services Scale-up service progressing engineered strains from bench to pilot scale under industrially relevant high cell density cultivation conditions, including fed-batch optimization. Processes frequently yield 10-60 g/L.
  • Enzyme Evolution and Screening Service evaluating evolved enzyme activity and characterizing new variants to identify improved enzymatic processes for industrial and specialty enzyme customers.
  • Protein Analysis Services Comprehensive product quality assessment including intact mass, glycan and disulfide bond profiling, in-vitro characterization, activity, binding affinity, and titer determination for customer proteins.
  • Upstream Process Characterization Service supporting characterization of upstream fermentation processes for customer protein production, complementing strain development and fermentation services.
  • Purification and Protein Quality Assessment Downstream processing service supporting purification of customer proteins from engineered E. coli strains, complementing upstream strain development and fermentation services.

Quantifiable outcome

  • Record titers >60 g/L for E. coli produced proteins
  • +6 more outcomes

Companies that use Vectron Biosolutions

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Vectron Biosolutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Vectron Biosolutions partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and secondary.

  • Cytovance BiologicscoreStrategic or Co-development Partner · 10 October 2023Strategic international collaboration to integrate Vectron's E. coli strain development services with Cytovance's microbial CDMO manufacturing capabilities. Enables customers to access complete package from gene to product for US market. Vectron brings next-generation vector engineering technologies while Cytovance provides cGMP manufacturing capacity including 1000L fermenters.
  • Motif FoodWorkscoreStrategic or Co-development Partner · 20 October 2022Partnership to develop next-generation animal-free proteins through precision fermentation. Vectron provides strain development expertise and proprietary expression technologies. Motif uses these for food technology applications including HEMAMI dairy alternatives and APPETEX texture enhancers. Expanded from existing 2-year collaboration.
  • Sartorius Korea Biotech Co.coreChannel Partner/ Reseller/ Distributor · 1 April 2022Exclusive distribution agreement making Sartorius Korea the exclusive agent for Vectron products and services in Republic of Korea. Provides Korean biotech and pharma companies easier access to Vectron's next-generation technologies for recombinant protein production.
  • Mycenax Biotech Inc.secondaryStrategic or Co-development Partner · 29 May 2019Non-exclusive collaboration offering superior complete solution for microbial production of therapeutic proteins. Combines Vectron's state-of-the-art strain development with Mycenax's cost-efficient manufacture from experienced CMO with great track record.
  • ArcticZymessecondaryOEM/ Whitelabel/ Licensing Partner · 20 December 2018Non-exclusive license agreement for recombinant expression of enzymes. Collaboration on two projects showed high success rate on large set of target enzymes in discovery pipeline and high yields in scaled-up production.
  • EnginZymesecondaryOEM/ Whitelabel/ Licensing Partner · 26 October 2016License agreement for commercial rights to use Vectron's expression vector technology platform for manufacture of Candida antarctica CalB enzyme for biocatalysis applications. Includes right to combine with EnginZyme's proprietary EziG immobilization matrix.
  • Scarab GenomicssecondaryStrategic or Co-development PartnerPartnership to engineer genetically stable E. coli strains optimized for perfusion fermentation. Scarab's early results show protein production sustained for nearly 60 days - approximately 20 times longer than typical E. coli strains. Combining with VB Secretion technology for extended fermentation processes.
  • SINTEFsecondaryImplementation/ SI/ Consulting PartnerResearch partner for Fab therapeutic protein production project funded by Norwegian Research Council. SINTEF contributes extensive experience with fed-batch fermentation to help develop Fab production processes targeting >10 g/L soluble Fabs.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Vectron Biosolutions competitors and assessment

Company assessment

Direct peers

  • ATUM: ATUM (formerly DNA2.0) provides proprietary expression vectors and microbial protein production services; directly comparable as a strain-engineering / protein-expression CRO with comparable target customers.
  • Cube Biotech: Cube Biotech offers expression systems and services for protein production in E. coli and other hosts, including difficult-to-express targets — directly overlapping with Vectron's tailor-made E. coli strain development offering.
  • ProteoGenix: ProteoGenix is a CRO providing recombinant protein expression and production services across hosts including E. coli; comparable customer base of biotech and pharma developers needing custom strain or construct work.
  • Cytovance Biologics: Cytovance is a microbial CDMO partnered with Vectron; comparable as a downstream microbial manufacturing provider and a partner that competes for similar strain-development-and-manufacturing opportunities.
  • Scarab Genomics: Scarab engineers stabilized E. coli strains and partners with Vectron on perfusion fermentation; comparable as a specialized E. coli engineering company serving similar difficult-protein production applications.

Emerging players

  • Bota Bio: Bota Bio is a synthetic biology / microbial biomanufacturing platform building engineered strains for industrial and specialty applications; comparable as a venture-backed microbial strain development platform, though broader in scope.

Broad incumbents

  • Codexis: Codexis engineers enzymes and proteins for pharmaceutical and industrial applications using directed evolution (CodeEvolver) — directly comparable technology overlap with Vectron's VB Evolution directed-evolution platform.
  • Ginkgo Bioworks: Ginkgo operates a much broader synthetic biology platform including cell engineering and protein production programs; comparable as a large-scale microbial engineering incumbent competing for similar strain-development wallet share.
  • Twist Bioscience: Twist provides synthetic DNA and antibody discovery/optimization services; adjacent to Vectron as an upstream provider enabling protein expression workflows, though broader and more diversified across life sciences.
  • WuXi Biologics: WuXi Biologics is a global biologics CDMO with microbial and mammalian capabilities; relevant benchmark as a scaled incumbent serving the same pharma/biotech customers who might otherwise engage Vectron for strain development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vectron Biosolutions social profiles

Digital presence

Vectron Biosolutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vectron Biosolutions leadership team

Management profile

Number of profiles

Profiles7 records

Vectron Biosolutions subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vectron Biosolutions funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vectron Biosolutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vectron Biosolutions

What does Vectron Biosolutions do?

Vectron Biosolutions develops tailor-made E. coli expression vector technologies and provides bespoke bacterial strain development services for recombinant protein production. The company delivers engineered production strains and research cell banks to pharmaceutical, biomanufacturing, and industrial enzyme customers, leveraging three proprietary technology platforms (VB Expression, VB Evolution, VB Secretion) under multi-phase project engagements that typically conclude with licensing of the developed strain to the customer.

Is Vectron Biosolutions a public or private company?

Vectron Biosolutions is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vectron Biosolutions founded?

Vectron Biosolutions was founded in 2008. It employs 1 to 10 people.

Where is Vectron Biosolutions based?

Vectron Biosolutions is headquartered in Trondheim, Norway, in the Europe region.

How does Vectron Biosolutions make money?

Three revenue lines are on record. Strain Development Services are the primary driver. The others are technology Licensing and patent Licensing.

Who are Vectron Biosolutions's main competitors?

Direct peers on record are ATUM, Cube Biotech, ProteoGenix, Cytovance Biologics and Scarab Genomics. Bota Bio is listed as an emerging player. Broad incumbents are Codexis, Ginkgo Bioworks, Twist Bioscience and WuXi Biologics.

Does Vectron Biosolutions have an API?

No public API is recorded for Vectron Biosolutions.

What industry is Vectron Biosolutions in?

Vectron Biosolutions's product category is Microbial protein production services. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals